Observational studyThrombosis research2021
Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome.
Observational study in Thrombosis research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 5 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- COVID-19 patients with acute pulmonary embolism have a higher mortality risk: systematic review and meta-analysis based on Italian cohorts.Journal of cardiovascular medicine (Hagerstown, Md.) · 2022Pooled it
- Incidence and prognostic value of pulmonary embolism in COVID-19: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Risk factors for pulmonary embolism in patients with COVID-19: a systemic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Tricuspid annular plane systolic excursion (TAPSE) measured by echocardiography and mortality in COVID-19: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Cumulative Evidence for the Association of Thrombosis and the Prognosis of COVID-19: Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- Pulmonary Embolism in Hospitalized COVID-19 Patients in Romania: Prevalence, Risk Factors, Outcomes.Viruses · 2025Article
- Prevalence and effects of pulmonary embolism on hospital outcomes among COVID-19 patients.BMC research notes · 2025Article
- Predictors of venous thromboembolic events in hospitalized patients with COVID-19.Journal of thrombosis and thrombolysis · 2025Article
- Interest of D-dimer level, severity of COVID-19 and cost of management in Gabon.World journal of critical care medicine · 2025Article
- Article
- Genetics of Long COVID: Exploring the Molecular Drivers of Persistent Pulmonary Vascular Disease Symptoms.Infectious disease reports · 2025Review
- Roles of oral anticoagulant use on the risk of 28-day mortality and in-hospital mortality in patients with acute respiratory distress syndrome.Frontiers in pharmacology · 2025Article
- Scoping review about pathogenesis, risk factors, and treatment of venous and arterial thrombosis in coronavirus infection.Frontiers in cardiovascular medicine · 2025Review
- Efficient management of pulmonary embolism diagnosis using a two-step interconnected machine learning model based on electronic health records data.Health information science and systems · 2024Article
- Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies.Life (Basel, Switzerland) · 2024Review
- Thromboembolic Disease and COVID-19: Experience of a University and Emergency Hospital During the Pandemic.Cureus · 2024Article
- Early pandemic in-hospital outcomes and mortality risk factors in COVID-19 solid organ transplant patients.Proceedings (Baylor University. Medical Center) · 2024Article
- Stratification of hypertension and SARS-CoV-2 infection by quantitative NMR spectroscopy of human blood serum.Communications medicine · 2023Article
- Investigating the prevalence of and predictive and risk factors for pulmonary embolism in patients with COVID-19 in Nemazee Teaching Hospital.Blood research · 2023Article
- Impact of Alteplase on Mortality in Critically Ill Patients with COVID-19 and Pulmonary Embolism.Viruses · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe incidence, characteristics, and prognosis of pulmonary embolism (PE) in Coronavirus disease 2019 (COVID-19) have been poorly investigated. We aimed to investigate the prevalence and the correlates with the occurrence of PE as well as the association between PE and the risk of mortality in COVID-19.
methodsRetrospective multicenter study on consecutive COVID-19 patients hospitalized at 7 Italian Hospitals. At admission, all patients underwent medical history, laboratory and echocardiographic evaluation.
resultsThe study population consisted of 224 patients (mean age 69 ± 14, male sex 62%); PE was diagnosed in 32 cases (14%). Patients with PE were hospitalized after a longer time since symptoms onset (7 IQR 3-11 days, 3 IQR 1-6 days; p = 0.001) and showed higher D-dimers level (1819 IQR 568-5017 ng/ml vs 555 IQR 13-1530 ng/ml; p < 0.001) and higher prevalence of myocardial injury (47% vs 28%, p = 0.033). At multivariable analysis, tricuspid annular plane systolic excursion (TAPSE; HR = 0.84; 95% CI 0.66-0.98; p = 0.046) and systolic pulmonary arterial pressure (sPAP; HR = 1.12; 95% CI 1.03-1.23; p = 0.008) resulted the only parameters independently associated with PE occurrence. Mortality rates (50% vs 27%; p = 0.010) and cardiogenic shock (37% vs 14%; p = 0.001) were significantly higher in PE as compared with non-PE patients. At multivariate analysis PE was significant associated with mortality.
conclusionPE is relatively common complication in COVID-19 and is associated with increased mortality risk. TAPSE and sPAP resulted the only parameters independently associated with PE occurrence in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.